Clinical Study

A Six-Month Randomized Controlled Trial of Whole Soy and Isoflavones Daidzein on Body Composition in Equol-Producing Postmenopausal Women with Prehypertension

Zhao-min Liu,1 Suzanne C. Ho,2 Yu-ming Chen,3 and Jean Woo1,4

1 Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong
2 Division of Epidemiology, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong
3 Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China
4 Division of Geriatrics, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong

Correspondence should be addressed to Suzanne C. Ho; suzanneho@cuhk.edu.hk and Jean Woo; jeanwoowong@cuhk.edu.hk

Received 28 February 2013; Accepted 27 May 2013

Academic Editor: Eric Doucet

Copyright © 2013 Zhao-min Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objectives. This paper reported the effects of commonly used whole soy foods (soy flour) and purified daidzein (one of the major isoflavones and the precursor of equol) on changes in anthropometric measurements and body composition in a 6-month double-blind, randomized, placebo-controlled trial among prehypertensive postmenopausal women who are also equol producers.

Methods. 270 eligible women were randomized to either one of the three treatments: 40 g soy flour (whole soy group), 40 g low-fat milk powder + 63 mg daidzein (daidzein group), or 40 g low-fat milk powder (placebo group) daily each for 6 months. Anthropometric indicators and body composition were measured before and after intervention.

Results. 253 subjects completed the study with good compliance. Urinary isoflavones levels suggested good compliance of subjects with supplementation. Whole soy and purified daidzein had no significant effect on body weight, body mass index (BMI), waist and hip circumferences, waist to hip ratio (WHR), body fat percentage, fat mass, and free fat mass. Conclusion. Six-month consumption of whole soy and purified daidzein at provided dosage had no improvement on body weight and composition compared with isocaloric milk placebo among prehypertensive equol-producing postmenopausal women. This trial is registered with ClinicalTrials.gov NCT01270737.

1. Introduction

Overweight and obesity are important clinical and public health burdens worldwide affecting more than 30% of adult population [1]. Aging- and menopause-induced estrogen deficiency results in an increase in body weight or abdominal fat and a decrease in lean mass which contribute to an elevated risk of cardiovascular diseases (CVD) and other metabolic disorders [2, 3]. Diet therapy has the lowest side effects for the prevention and management of postmenopausal obesity relative to hormone replacement therapy [4]. Soy is a traditional Asian diet and also a rich source of plant protein, unsaturated fat, dietary fiber, isoflavones (one major phytoestrogen), saponin, and so forth with a potential role on fat mass reduction and weight control.

Laboratory and animal studies are generally supportive for soy and/or its components when isocaloric diets are administered to promote weight and fat loss by increasing energy utilization [5], reducing fat accumulation [6], and promoting a select loss of visceral adipose tissue [7] with more benefits than those of casein or other animal foods [8, 9]. Several observational studies [10–12], but not all [13], have reported that soy or isoflavone correlated with lower body mass index (BMI), waist circumference (WC), or body fat mass. However, clinical trials indicated inconsistent findings. Some studies reported a favorable effect with soy protein or isoflavones intake on body weight and fat mass reduction [14–17], while others not [18–21]. The differences in population characteristics, types of soy products, duration of intervention, methods for outcome measures, capacity
2. Methods

2.1. Subjects Recruitment. The study was a randomized, double-blind, placebo-controlled trial. The enrollment of participants was conducted from December 2010 to January 2012 in local community through advertisements in newspaper. Participants were initially screened by telephone interview and their equol-producing phenotypes were then confirmed by consecutive intake of 63 mg daidzein for 7 days and collection of 24 h urine for isoflavones testing. Written informed consent was obtained from each participant prior to enrolment. The institutional review boards of the Chinese University of Hong Kong approved the study protocol.

The eligible subjects were Hong Kong Chinese women aged 48–65 y; at least 1 year menopausal; mean SBP above 120 mmHg, DBP above 80 mmHg, or both; equol producers which were defined as 24-hour urinary log_{10} S-equol/daidzein ratio greater than −1.75 after daidzein challenge [29]. Subjects were excluded if they were currently or in preceding 6 months taking antihypertensive, hypoglycemic, or weight reduction agents or on hormone therapy; had a history of stroke, coronary heart diseases, untreated thyroid diseases, severe liver, and renal dysfunction; have breast, uterine, or ovarian cancer or other malignancies in previous 10 years; on prescribed weight control or vegetarian diet; with known soy or milk allergy.

2.2. Study Power. With a planned number of subjects of 90 in each arm (270 subjects in total) and given the current SD of changes in body weight and fatness percentage, we would have 80% power to find a 0.75 kg change in the body weight (SD of change 2.2 kg) and 0.72% in the change of body fat percentage (SD of change 2.1%), based on a convention assumption of α level 0.05 (for a 2-side t-test) and allowing for 10% withdrawal rate.

2.3. Randomization. A block randomization was used for subject assignment in random block sizes of 6, 9, and 12. The 270 continuous serial numbers were divided into 30 blocks. A list of random numbers was computer generated and each random number corresponds with 1 of the 3 possible interventions. 270 serial numbers were labeled on the identically looking boxes of supplements by personnel not involved in the trial and assigned to eligible subjects according to the sequence of their visits. All the research staff, technicians, and subjects were blinded to the treatment codes. To assess blinding, we asked the participants which group they thought they had been assigned to at the end of the trial. The rates of correct estimation of allocation were 7.8%, 7.8%, and 6.5% in whole soy, daidzein, and placebo groups, respectively (P = 0.947), indicating the blinding was effective.

2.4. Intervention and Supplement Preparation. Eligible participants were randomized to one of the 3 groups: 40 g soy flour (whole soy group), 40 g low-fat milk powder + 63 mg daidzein (daidzein group), or 40 g low-fat milk powder (placebo group) daily each for 6 month. The 3 kinds of supplements were processed into beverage powder with similar color, odor, and major nutrients profile by addition of minerals, starch, or other food additives. Table 1 indicated the nutrient profiles of the 3 supplements. The daily dose was filled into identical looking sachets. The products were tested prior to and after packaging to ensure content uniformity. The supplements were suggested to be mixed with 300 mL of water or beverages and partially replace breakfast or snacks. Participants were asked not to take supplements containing phytoestrogen or other extracts known to affect outcome measures, minimize their intake of soy foods (≤2 servings per week), refrain from high salt diet, restrict alcohol intake (≤2 drinks per week), and maintain their usual level of physical activity. They were required to return the unconsumed sachets at each followup to assess their adherence. A monthly telephone interview was conducted during the intervention and any changes in diet, physical activity, health status, and medications were monitored by research staff.

2.5. Data Collection. Individual information was collected by trained interviewers by face-to-face interview based on a structured questionnaire on sociodemographic data, years since menopause, medical history, medication, dietary habits and physical activities, and so forth. Dietary intakes over
intervention were evaluated by 3-day food diary which was recorded by subjects at baseline and at the end of the trial. Subjects received a 30-min training on estimation of food amounts, portion and utensil sizes. Dietary nutrients (energy, protein, total fat, calcium and soy isoflavones) were calculated based on the China Food Composition Table [30].

2.6. Anthropometric Measurements and Body Composition. Anthropometric indicators and body composition were measured at baseline and end of the trial. Body weight was measured with the subjects on light clothing without shoes by using the beam balance scales (Detecto, Clinicon Medical LTD, USA) and recorded to the nearest 0.1 kg. Height was measured in a standing position without shoes by using a wall-mounted stadiometer. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Waist circumference was measured at the level midway between the lowest rib and the iliac crest using a nonelastic tape without any pressure to body. Hip circumference was measured at the level of the greater trochanters. WHR was calculated as the ratio of waist-to-hip circumferences. All measurements were performed twice by the same research staff and the average was recorded.

Body fat percentage (BF%), fat mass (FM), and free fat mass (FFM) were assessed by bioelectrical impedance analyzer (BIA, TBF-410-GS Tanita Body Composition Analyzer, Japan). The BF% was calculated from the impedance value as well as the preentered personal particulars including weight, height, age, and sex through a build-in software [31]. These measurements were done after 10–12 hours fasting. Subjects were requested to refrain from strenuous exercise and empty their bladders before the measurements. The coefficients of variation for repeated measures were all less than 5% for BF%, FM, and FFM.

2.7. Statistical Analysis. Statistical analysis was performed with the use of SPSS 16.0 software. Results were considered significant if the two-tailed P value was <0.05. Baseline characteristics, dietary intake, and physical activity level were compared among the 3 study groups by analysis of variance (ANOVA). Data were analysed according to an intention-to-treat principle including all 270 subjects who were randomized. The last value carried forward was used for any missing data at followups. The changes and percentage changes at 6-month in outcome variables among the 3 study groups were compared by ANOVA. Bonferroni test was used for Post Hoc multiple comparisons. We tested the effect modification by adding interaction terms of intervention and subgroup variables to the univariate model. A further stratification analysis was conducted to examine whether the effect was differed by baseline BMI level and years since menopause.

2.8. Assessment of Compliance. Compliance with treatment was assessed by counting the returned supplements for estimation of percentage of intake, food diary and 24-h urinary excretion of isoflavones at baseline and at 6 months. Urinary isoflavones were tested by high performance liquid chromatography (HPLC) [32]. Adherence was good and did not differ among the 3 groups.

3. Results

Overall 270 eligible women were randomized into 3 intervention arms. Seventeen (6.3%) subjects withdrew: 5 in the whole soy group, 3 in the daidzein group, and 9 in the placebo group. There was no significant difference in dropout rates between the 3 groups (P = 0.172). Detailed study flow and reasons of withdrawal were indicated in Figure 1. Subjects who withdrew from the study were also invited for follow-up visits with 265 subjects attending the final visit.

Baseline characteristics (Table 2) were similar among the 3 study groups in terms of age, menopausal year, BMI, SBP and DBP, education, medical history, medication, dietary habits, and physical activity. There was no significant difference in the baseline and follow-up dietary intake in total energy, protein, total fat, and soy isoflavones among the 3 study groups.

No significant difference was observed in the 6-month change or %changes in body weight, BMI, waist and hip circumferences, WHR, body fat%, fat mass, and free fat mass among the 3 study groups (Table 3). There was no significant interaction between intervention and years since menopause, however, a significant interaction in intervention and basal body weight (P = 0.03). Further subgroup analysis among subjects with BMI > 24 suggested a notable reduction in BMI and WHR with milk placebo intake.

3.1. Adverse Events. A total 182 adverse events were reported, approximately equally distributed among the 3 treatment phases. The most common complaints were gastrointestinal discomfort (n = 166), sore throat (n = 21), weight gain (n = 18), rash (n = 13), and feelings of breast swelling (n = 7, 2 in soy flour group, 3 in daidzein group, and 2 in placebo group). Two women in the daidzein group, both within 3 years since menopause, reported a 2–3 days episode of vaginal bleeding after 2 months’ intervention. No recurrence and abnormalities were reported.
726 women attended screening visits
648 donated 24 h urine for equol testing
300 equol producers confirmed
270 randomized
14 noncompliance
9 quit by themselves
7 intake medications

Whole soy group
n = 90
88 attended final visit
85 valid completers
5 dropouts with reasons
1 GI discomfort
2 time constraint
2 start BP-lowering treatments
Included in final analysis n = 90

Daidzein group
n = 90
90 attended final visit
87 valid completers
3 dropouts with reasons
1 GI discomfort
1 skin allergy
1 start BP-lowering treatment
Included in final analysis n = 90

Placebo group
n = 90
87 attended final visit
81 valid completers
3 dropouts with reasons
1 GI discomfort
1 skin allergy
3 start BP-lowering treatments
2 develop tumors
Included in final analysis n = 90

Figure 1: GI discomfort: gastrointestinal discomfort; BP: blood pressure; Whole soy group: intake 40 g soy flour per day; Daidzein group: intake 63 mg daidzein + 40 g low-fat milk powder per day; Placebo group: intake 40 g low-fat milk powder per day.

3.2. Compliance. The consumption of supplements from those provided (including dropouts) were 93.3% in the whole soy group, 94.4% in the daidzein group, and 92.9% in the placebo group throughout the trial. Ninety-nine participants were randomly selected for final 24 h urinary isoflavones testing for compliance assessment. The purpose of final urine collection was not disclosed to subjects. Urinary genistein and glycetin increased 7.0 and 4.2-fold in whole soy group, while urinary daidzein and equol increased 4.7- and 6.6-fold in daidzein group with no change in milk placebo group, indicating good compliance among participants.

4. Discussion

Our 6-month double-blind randomized placebo-controlled trial among prehypertensive, equol-producing postmenopausal women demonstrated that whole soy (containing 12.8 g/d soy protein) and purified daidzein (63 mg/day) had no significant effect on anthropometric parameters and body composition compared with isocaloric milk placebo.

Although data from animal models generally support a favorable effect of soy consumption on weight and fat loss, results from clinical trials are still controversial. Our findings are in line with several previous RCTs [19, 21, 33–35] in which soy protein has no better effect on body weight and composition than milk or animal products. A 12-month RCT [34] among older postmenopausal women (60–75 y) reported that 25.6 g soy protein containing 99 mg isoflavones had no effect on BMI and WHR compared with milk protein. Women at different menopausal stages may response differently to soy supplementation; however, our subgroup analysis among women in early menopause (<4 years) did not suggest a different effect compared with women in late menopause. Another 20-week RCT [19] even reported that formula food containing milk protein is superior to that containing soy protein for reducing visceral and subcutaneous fat. A 23-week RCT [20] also indicated that whey protein but not soy protein supplementation alters body weight and composition in overweight and obese adults. Our results also indicated a trend of reduction in body weight with milk placebo intake ($P = 0.095$), at least implying that soy consumption does not have advantage over low-fat milk on weight and fat loss. Previous evidence also supported that there is no difference in satiety between dietary soy protein, other vegetable proteins, and animal protein [36, 37]. As in many other studies, we used milk product to serve as the placebo. However, milk peptides may have active biological properties relevant to weight loss and obesity [38], thus comparing two biologically active interventions (soy and milk) may blunt the potentially notable effect of soy.

The nonsignificant findings in our study may be explained by the fact that most of our participants were not overweight or obese at the start of the trial. The average BMI of our
Table 2: Baseline characteristics among 3 study groups.

|                                | Whole soy group | Daidzein group | Placebo group | P value |
|--------------------------------|-----------------|----------------|---------------|---------|
| Age (y)                        | 57.6 ± 5.3      | 57.7 ± 5.0      | 58.5 ± 4.7    | 0.464   |
| Menopausal years (y)           | 9.0 ± 6.4       | 8.9 ± 5.7       | 9.1 ± 5.2     | 0.977   |
| BS Total PA (MET min/d)        | 1251.3 ± 726.4  | 1218.5 ± 625.1  | 1134.2 ± 534.7| 0.450   |
| Job PA                         | 476.6 ± 565.3   | 453.8 ± 618.7   | 386.9 ± 594.5 | 0.574   |
| House PA                       | 550.6 ± 571.2   | 568.6 ± 506.6   | 509.1 ± 340.9 | 0.700   |
| Exercise PA                    | 221.6 ± 200.2   | 191.6 ± 178.8   | 229.2 ± 206.3 | 0.403   |
| BS dietary intake              |                 |                |               |         |
| Energy (kcal/d)                | 2048.3 ± 543.2  | 2090.4 ± 655.25 | 1983.5 ± 431.6| 0.341   |
| Protein (g/d)                  | 88.9 ± 22.7     | 90.1 ± 29.4     | 86.1 ± 20.6   | 0.373   |
| Fat (g/d)                      | 64.9 ± 21.8     | 69.0 ± 22.6     | 63.4 ± 37.1   | 0.386   |
| Isoflavones (mg/d)             | 14.6 ± 10.1     | 14.2 ± 8.5      | 14.5 ± 9.5    | 0.852   |
| Dietary intake at 6 month      |                 |                |               |         |
| Energy (kcal/d)                | 1956.2 ± 475.65 | 2006.9 ± 560.6  | 1938.7 ± 391.1| 0.443   |
| Protein (g/d)                  | 82.6 ± 21.9     | 80.8 ± 27.5     | 76.5 ± 18.4   | 0.368   |
| Fat (g/d)                      | 61.5 ± 19.8     | 63.6 ± 15.8     | 60.4 ± 23.9   | 0.325   |
| Isoflavones (mg/d)             | 8.6 ± 6.6       | 8.3 ± 7.5       | 7.9 ± 7.2     | 0.714   |
| Job status                     |                 |                |               | 0.128   |
| housewife                      | 37 (13.7%)      | 46 (17.0%)      | 54 (20.0%)    |         |
| Part-time job                  | 26 (9.6%)       | 18 (6.7%)       | 16 (5.9%)     |         |
| Full-time job                  | 27 (10.0%)      | 26 (9.6%)       | 20 (7.4%)     |         |
| Ever use of lipid-lowering medication | 8 (7.5%) | 8 (7.5%)       | 8 (7.5%)     | 0.915   |
| Ever use of HRT                | 9 (3.3%)        | 13 (4.8%)       | 19 (7.0%)     | 0.112   |
| Ever use of contraceptives     | 46 (17.0%)      | 39 (14.4%)      | 45 (16.7%)    | 0.528   |
| Passive smoking                | 13 (4.8%)       | 12 (4.4%)       | 15 (5.6%)     | 0.814   |
| Regular alcohol drinking       | 7 (2.6%)        | 8 (3.0%)        | 10 (3.7%)     | 0.738   |
| Regular coffee drinking        | 34 (12.6%)      | 37 (13.7%)      | 32 (11.9%)    | 0.742   |
| Regular tea drinking           | 73 (32.7%)      | 73 (32.7%)      | 77 (34.5%)    | 0.662   |

Data are presented as mean ± standard deviation for continuous variables or number (%) for categorical variables. ANOVA test for continuous variables and Chi-square test for categorical variables. BS indicates baseline; PA indicates physical activity; HRT indicates hormone replacement treatment; Regular drinking means drinking alcohol, tea, or coffee more than 1 time per week. METs are multiples of resting metabolic rates and an MET minute is computed by multiplying the MET score of an activity by the minutes performed. Dietary nutrient intakes were calculated mainly based on the China Food Composition Table 2002 and 2004.

Although our previous RCT [42] reported a mild but significant effect with 15 g soy protein and 100 mg isoflavones on anthropometric measures relative to milk protein, a study by Moeller et al. [40] using a higher dosage of soy protein (40 g soy protein and 80.4 mg isoflavones) did not affect body fat and lean mass compared to whey protein. In the present study, we used a daily dose of 40 g soy flour which contains 12.8 g soy protein and 49 mg isoflavones representing a highly normal range of a typical soy intake in Asian countries [43]. This amount corresponds to the recommendation of the Chinese Nutrition Society of daily intake of 30–50 g soy products [44]. A higher dosage may strongly modify the dietary habits of participants and affect the compliance during a relatively long-term treatment. In addition, studies have shown that isolated soy component is not as effective as intact soy foods on improvement of cardiovascular health [45]. Moreover, Asia women with similar study age (45–65 y) have conventionally high soy food consumption, which could possibly neutralize the treatment effect of soy. To avoid
### Table 3: The effect of whole soy and purified daidzein on anthropometric measures and body composition.

| Measure                        | Whole soy group  | Daidzein group  | Placebo group | P values |
|-------------------------------|------------------|-----------------|---------------|---------|
| **Body weight (kg)**          |                  |                 |               |         |
| Baseline                      | 56.6 ± 7.33      | 56.3 ± 9.18     | 57.7 ± 9.01   | 0.552   |
| 6-month                       | 56.5 ± 7.21      | 57.0 ± 9.16     | 57.0 ± 8.45   | 0.901   |
| Change                        | 0.20 ± 1.78      | 0.59 ± 3.35     | −0.20 ± 1.53  | 0.095   |
| %change                       | 0.399 ± 3.346    | 1.272 ± 6.971   | −0.311 ± 2.649| 0.092   |
| **Body mass index (BMI, kg/m²)** |                  |                 |               |         |
| Baseline                      | 23.4 ± 2.78      | 23.2 ± 3.46     | 23.7 ± 3.34   | 0.552   |
| 6-month                       | 23.5 ± 2.78      | 23.5 ± 3.42     | 23.6 ± 3.21   | 0.964   |
| Change                        | 0.163 ± 0.758    | 0.331 ± 1.388   | 0.037 ± 0.622 | 0.143   |
| %change                       | 0.746 ± 3.331    | 1.672 ± 7.073   | 0.171 ± 2.574 | 0.112   |
| **Waist circumference (WC, cm)** |                  |                 |               |         |
| Baseline                      | 79.1 ± 7.70      | 78.1 ± 8.33     | 78.4 ± 8.84   | 0.693   |
| 6-month                       | 78.1 ± 7.85      | 77.4 ± 8.41     | 76.9 ± 7.90   | 0.600   |
| Change                        | −0.816 ± 2.779   | −0.706 ± 2.503  | −1.039 ± 2.725| 0.701   |
| %change                       | −0.991 ± 3.522   | −0.877 ± 3.130  | −1.217 ± 3.298| 0.787   |
| **Hip circumference (HC, cm)** |                  |                 |               |         |
| Baseline                      | 93.1 ± 5.88      | 93.1 ± 7.09     | 93.8 ± 7.04   | 0.736   |
| 6-month                       | 93.0 ± 6.02      | 93.1 ± 7.10     | 93.1 ± 6.55   | 0.995   |
| Change                        | −0.094 ± 1.627   | 0.009 ± 1.547   | −0.195 ± 1.547| 0.691   |
| %change                       | −0.092 ± 1.792   | 0.019 ± 1.664   | −0.194 ± 1.660| 0.708   |
| **Waist and hip ratio (WHR)** |                  |                 |               |         |
| Baseline                      | 0.848 ± 0.047    | 0.838 ± 0.047   | 0.834 ± 0.052 | 0.137   |
| 6-month                       | 0.839 ± 0.044    | 0.830 ± 0.049   | 0.826 ± 0.050 | 0.171   |
| Change                        | −0.008 ± 0.0265  | −0.008 ± 0.022  | −0.009 ± 0.024| 0.937   |
| %change                       | −0.899 ± 3.073   | −0.899 ± 2.561  | −1.026 ± 2.821| 0.942   |
| **Body fat percentage (%)**   |                  |                 |               |         |
| Baseline                      | 30.5 ± 5.87      | 30.5 ± 6.55     | 30.6 ± 6.41   | 0.992   |
| 6-month                       | 30.7 ± 6.01      | 30.1 ± 6.17     | 30.4 ± 5.94   | 0.812   |
| Change                        | 0.159 ± 2.104    | −0.382 ± 2.241  | 0.122 ± 2.087 | 0.180   |
| %change                       | 0.691 ± 6.805    | −0.786 ± 7.378  | 0.507 ± 6.421 | 0.306   |
| **Fat mass (kg)**             |                  |                 |               |         |
| Baseline                      | 17.4 ± 5.30      | 17.9 ± 6.69     | 18.0 ± 6.56   | 0.831   |
| 6-month                       | 17.6 ± 5.54      | 17.5 ± 6.04     | 17.6 ± 6.06   | 0.991   |
| Change                        | 0.233 ± 1.584    | −0.310 ± 1.844  | 0.099 ± 1.669 | 0.092   |
| %change                       | 1.517 ± 9.440    | −0.542 ± 9.400  | 0.550 ± 8.055 | 0.319   |
| **Free fat mass (kg)**        |                  |                 |               |         |
| Baseline                      | 38.6 ± 3.62      | 38.8 ± 4.08     | 39.1 ± 3.51   | 0.673   |
| 6-month                       | 38.7 ± 3.23      | 38.9 ± 5.63     | 38.9 ± 3.21   | 0.894   |
| Change                        | 0.165 ± 0.956    | 0.121 ± 3.484   | −0.129 ± 1.198| 0.640   |
| %change                       | 0.519 ± 2.499    | 0.200 ± 9.867   | −0.223 ± 2.796|         |

All values are means ± standard deviation; P values refer to comparison among the 3 study groups by ANOVA (analysis of variance); *Skewed variables or variables with heterogeneity in variance (Body fat%) were corrected by log transformation and reported arithmetic means.

Possible ceiling effect, we instructed our subjects to reduce their habitual soy intake to no more than 2 servings per week. The dietary assessment at baseline and the end of trial indicated that a good dietary compliance of subjects with a reduction of average isoflavones intake decreased from 14.5 to 8.3 g/d. Thus, the soy dosage in our study seems unlikely to be the key issue of the effect of soy.

The study has several limitations. Firstly, the use of bioelectrical impedance method (BIA) for body composition measures had advantages but also limitations. Body fat should ideally be measured by the golden standards, densitometry (underwater weighing), or dual X-ray absorptiometry (DXA), but these two methods are generally expensive and impractical for epidemiologic study. BIA is a practical...
and good alternative [46, 47] with established validity and reliability in the assessment of body composition [48, 49]. The precision error of BIA is similar to DXA and UW [50]. BIA instrument used in our study also has limitation in differentiating regional fat from total fat mass, as evidence has shown that central adiposity is more strongly associated with CVD than peripheral adiposity [51]. However in our study the change in waist circumference (a validated indicator of intra-abdominal adipose tissue) did not differed among the 3 study arms. Secondly, milk product may not be an adequate “placebo” for investigating the effects of soy on body weight control. In addition, the increase in protein and energy intake due to supplementation may have overshadowed the treatment effect.

To our knowledge, this is the first RCT concomitantly comparing the effects of commonly used whole soy foods (soy flour) and potential active soy component of daidzein among equol-producing women, a susceptible population to benefit from soy intervention. This study was a randomized, double-blind, placebo-controlled trial with a relatively large sample size. Subjects’ compliance was good and the attrition rate was only 6.3%. The study also had successful blindness efficacy. Three supplements were formulated into isocaloric powder with similar nutrient profiles. Furthermore, dietary intake and physical activity were stable across the whole intervention which was unlikely to confound the effects of soy. To better ensure participant compliance with treatment, we qualitatively measured urinary excretion of isoflavones at baseline and the end of the trial. Also, participants were instructed to restrict their usual soy intake to no more than 2 servings of soy foods per week to avoid a potential “ceiling effect” of soy. Finally, based on the number of participants who completed the intervention, this study was well powered to detect a small change in body weight and body fatness.

5. Conclusion

The 6-month RCT among equol-producing postmenopausal women with prehypertension or hypertension indicates that soy consumption does not exert an advantage over low-fat milk product for weight and fat loss when prescribed at isocaloric levels. Future trials among overweight or obese patients, using more elaborate techniques to assess body composition are warranted.

Conflict of Interests

All the authors declare no conflict of interests. Neither the RGC-GRF or Soy and Dairy Company had any role in the design and conduct of the study; the collection, analysis, and interpretation of the data; or the preparation, review, or approval of the paper.

Authors’ Contribution

Professor Suzanne C. Ho, Professor Yu-ming Chen, Dr. Zhao-min Liu, and Professor Jean Woo conceptualized and designed the trial and obtained the grant. Dr. Zhao-min Liu conducted data collection, analyzed the data and drafted the paper. Professor Yu-ming Chen helped in urine analysis of isoflavones and dietary assessment and biochemical testing. All the authors contributed to the paper preparation and helped in results explanation.

Acknowledgments

The study was funded by Hong Kong Research Grant Committee-General Research Fund (RGC-GRF465810). The authors are indebted to their study participants and the research assistants. Without their effort, this investigation would not have been possible.

References

[1] T. Kelly, W. Yang, C. S. Chen, K. Reynolds, and J. He, “Global burden of obesity in 2005 and projections to 2030,” International Journal of Obesity, vol. 32, no. 9, pp. 1431–1437, 2008.
[2] I. Elmadfa and A. L. Meyer, “Body composition, changing physiological functions and nutrient requirements of the elderly,” Annals of Nutrition and Metabolism, vol. 52, supplement 1, pp. 2–5, 2008.
[3] M. L. Misso, C. Jang, J. Adams et al., “Differential expression of factors involved in fat metabolism with age and the menopause transition,” Maturitas, vol. 51, no. 3, pp. 299–306, 2005.
[4] S. Sipilä, “Body composition and muscle performance during menopause and hormone replacement therapy,” Journal of Endocrinological Investigation, vol. 26, no. 9, pp. 893–901, 2003.
[5] N. Vaughn, A. Rizzo, D. Doane, J. L. Beverly, and E. G. de Mejía, “Intracerebroventricular administration of soy protein hydrolysates reduces body weight without affecting food intake in rats,” Plant Foods for Human Nutrition, vol. 63, no. 1, pp. 41–46, 2008.
[6] C. R. Cederoth, M. Vinciguerra, A. Ginovci et al., “Dietary phytoestrogens activate AMP-activated protein kinase with improvement in lipid and glucose metabolism,” Diabetes, vol. 57, no. 5, pp. 1176–1185, 2008.
[7] M. T. Velasquez and S. J. Bhathena, “Role of dietary soy protein in obesity,” International Journal of Medical Sciences, vol. 4, no. 2, pp. 72–82, 2007.
[8] T. Aoyama, K. Fukui, K. Takamatsu, Y. Hashimoto, and T. Yamamoto, “Soy protein isolate and its hydrolysate reduce body fat of dietary obese rats and genetically obese mice (yellow KK),” Nutrition, vol. 16, no. 5, pp. 349–354, 2000.
[9] A. Naaz, S. Yellayi, M. A. Zakroczymski et al., “The soy isoflavone genistein decreases adipose deposition in mice,” Endocrinology, vol. 144, no. 8, pp. 3315–3320, 2003.
[10] J. R. Guthrie, M. Ball, A. Murkies, and L. Dennerstein, “Dietary phytoestrogen intake in mid-life Australian-born women: relationship to health variables,” Climacteric, vol. 3, no. 4, pp. 254–261, 2000.
[11] Y. Yamori, “Worldwide epidemic of obesity: hope for Japanese diets,” Clinical and Experimental Pharmacology & Physiology, vol. 31, supplement 2, pp. S2–S4, 2004.
[12] D. Goodman-Gruen and D. Kritz-Silverstein, “Usual dietary isoflavone intake and body composition in postmenopausal women,” Menopause, vol. 10, no. 5, pp. 427–432, 2003.
[13] M. C. Nachtigal, R. E. Patterson, K. L. Stratton, L. A. Adams, A. L. Shattuck, and E. White, “Dietary supplements and weight
control in a middle-age population," *Journal of Alternative and Complementary Medicine*, vol. 11, no. 5, pp. 909–915, 2005.

[14] S. Choquette, E. Riesco, E. Cormier, T. Dion, M. Aubertin-Leheudre, and I. J. Dionne, "Effects of soya isoflavones and exercise on body composition and clinical risk factors of cardiovascular diseases in overweight postmenopausal women: a 6-month double-blind controlled trial," *The British Journal of Nutrition*, vol. 105, no. 8, pp. 1199–1209, 2011.

[15] D. R. Christie, J. Grant, B. E. Darnell, V. R. Chapman, A. Gastaldelli, and C. K. Sites, "Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial," *The American Journal of Obstetrics and Gynecology*, vol. 203, no. 2, pp. 153.e1–153.e9, 2010.

[16] C. K. Sites, B. C. Cooper, M. J. Toth, A. Gastaldelli, A. Arabshahi, and S. Barnes, "Effect of a daily supplement of soy protein on body composition and insulin secretion in postmenopausal women," *Fertility and Sterility*, vol. 88, no. 6, pp. 1609–1617, 2007.

[17] F. Liao, M. Shihe, S. Yang, S. Lin, and Y. Chien, "Effectiveness of a soy-based compared with a traditional low-calorie diet on weight loss and lipid levels in overweight adults," *Nutrition*, vol. 23, no. 7–8, pp. 551–556, 2007.

[18] L. Azadbakht and S. Nurbakhsh, "Effect of soy drink replacement in a weight reducing diet on anthropometric values and blood pressure among overweight and obese female youths," *Asia Pacific Journal of Clinical Nutrition*, vol. 20, no. 3, pp. 383–389, 2011.

[19] T. Song, K. Barua, G. Buseman, and P. A. Murphy, "Soy isoflavone analysis: quality control and a new internal standard," *The American Journal of Clinical Nutrition*, vol. 68, no. 6, supplement, pp. 1474S–1479S, 1998.

[20] M. St-Onge, N. Claps, C. Wolper, and S. B. Heymsfield, "Supplementation alters body weight and composition in free-living overweight and obese adults," *Journal of Nutrition*, vol. 141, no. 8, pp. 1489–1494, 2011.

[21] J. W. Anderson, J. Fuller, K. Patterson, R. Blair, and A. Tábor, "Soy compared to casein meal replacement shakes with energy-restricted diets for obese women: randomized controlled trial," *Metabolism: Clinical and Experimental*, vol. 56, no. 2, pp. 280–288, 2007.

[22] J. Wu, J. Oka, J. Ezaki et al., "Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial," *Menopause*, vol. 14, no. 5, pp. 866–874, 2007.

[23] R. S. Muthyala, Y. H. Ju, S. Sheng et al., "Equol, a natural estrogenic metabolite from soy isoflavones: convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta," *Bioorganic and Medicinal Chemistry*, vol. 12, no. 6, pp. 1559–1567, 2004.

[24] K. D. R. Setchell, N. M. Brown, and E. Lydekking-Olsen, "The clinical importance of the metabolite equol—a clue to the effectiveness of soy and its isoflavones," *Journal of Nutrition*, vol. 132, no. 12, pp. 3577–3584, 2002.

[25] F. K. Welty, K. S. Lee, N. S. Lew, and J. Zhou, "Effect of soy nuts on blood pressure and lipid levels in hypertensive, prehypertensive, and normotensive postmenopausal women," *Archives of Internal Medicine*, vol. 167, no. 10, pp. 1060–1067, 2007.

[26] S. Kreijkamp-Kaspers, L. Kok, M. L. Bots, D. E. Grobbee, J. W. Lampe, and Y. T. van der Schouw, "Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women," *The American Journal of Clinical Nutrition*, vol. 81, no. 1, pp. 189–195, 2005.

[27] L. Hooper, P. A. Kroon, E. B. Rimm et al., "Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials," *The American Journal of Clinical Nutrition*, vol. 88, no. 1, pp. 38–50, 2008.

[28] M. Messina, J. W. Lampe, D. F. Birt et al., "Reductionism and the narrowing nutrition perspective: time for reevaluation and emphasis on food synergy," *Journal of the American Dietetic Association*, vol. 101, no. 12, pp. 1416–1419, 2001.

[29] K. D. R. Setchell and S. J. Cole, "Method of defining equol-producer status and its frequency among vegetarians," *Journal of Nutrition*, vol. 136, no. 8, pp. 2188–2193, 2006.

[30] Y. Yue-Xin, *China Food Composition 2002*, Institute of Nutrition and Food Safety, Peking University Medical Press, Beijing, China, 2002.

[31] H. C. Lukaski, P. E. Johnson, W. W. Bolonchuk, and G. I. Lykken, "Assessment of fat-free mass using bioelectrical impedance measurements of the human body," *The American Journal of Clinical Nutrition*, vol. 41, no. 4, pp. 810–817, 1985.

[32] J. Nestel, "Arterial compliance, blood pressure, plasma leptin, and biological activity through estrogen receptors alpha and beta," *Bioorganic and Medicinal Chemistry*, vol. 12, no. 6, pp. 1559–1567, 2004.

[33] N. Maestas, J. Macias, J. Macias, and F. Sandoval, "The narrowing nutrition perspective: time for reevaluation and emphasis on food synergy," *Journal of the American Dietetic Association*, vol. 101, no. 12, pp. 1416–1419, 2001.

[34] L. Kok, S. Kreijkamp-Kaspers, D. E. Grobbee, J. W. Lampe, and Y. T. van der Schouw, "Soy isoflavones, body composition, and physical performance," *Maturitas*, vol. 52, no. 2, pp. 102–110, 2005.

[35] T. Yamashita, T. Sasaahara, S. E. Pomeroy, G. Collier, and P. J. Nestel, "Arterial compliance, blood pressure, plasma leptin, and plasma lipids in women are improved with weight reduction equally with a meat-based diet and a plant-based diet," *Metabolism: Clinical and Experimental*, vol. 47, no. 11, pp. 1308–1314, 1998.

[36] V. Lang, F. Bellisle, J. Oppert et al., "Satiating effect of proteins in healthy subjects: a comparison of egg albumin, casein, gelatin, soy protein, pea protein, and wheat gluten," *The American Journal of Clinical Nutrition*, vol. 67, no. 6, pp. 1197–1204, 1998.

[37] V. Lang, F. Bellisle, C. Alamowitch et al., "Varying the protein source in mixed meal modifies glucose, insulin and glucagon kinetics in healthy men, has weak effects on subjective satiety and fails to affect food intake," *European Journal of Clinical Nutrition*, vol. 53, no. 12, pp. 959–965, 1999.

[38] A. S. Yalcın, "Emerging therapeutic potential of whey proteins and peptides," *Current Pharmaceutical Design*, vol. 12, no. 13, pp. 1637–1643, 2006.

[39] N. Maestas, E. A. P. Nahas, J. Nahas-Neto et al., "Effects of soy protein and resistance exercise on body composition and blood lipids in postmenopausal women," *Maturitas*, vol. 56, no. 4, pp. 350–358, 2007.

[40] L. E. Moeller, C. T. Peterson, K. B. Hanson et al., "Isoflavone-rich soy protein prevents loss of hip lean mass but does not prevent the shift in regional fat distribution in perimenopausal women," *Menopause*, vol. 10, no. 4, pp. 322–331, 2003.
[41] D. B. Allison, G. Gadbury, L. G. Schwartz et al., “A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial,” European Journal of Clinical Nutrition, vol. 57, no. 4, pp. 514–522, 2003.

[42] Z. M. Liu, S. C. Ho, Y. M. Chen, and Y. P. Ho, “A mild favorable effect of soy protein with isoflavones on body composition: a 6-month double-blind randomized placebo-controlled trial among Chinese postmenopausal women,” International Journal of Obesity, vol. 34, no. 2, pp. 309–318, 2010.

[43] M. Messina and V. Messina, “The role of soy in vegetarian diets,” Nutrients, vol. 2, no. 8, pp. 855–888, 2010.

[44] C. N. Society, “Dietary Guidelines for Chinese Residents 2007,” 2007, http://www.cnsoc.org/.

[45] T. B. Clarkson and M. S. Anthony, “Phytoestrogens and coronary heart disease,” Bailliere’s Clinical Endocrinology and Metabolism, vol. 12, no. 4, pp. 589–604, 1998.

[46] A. M. Prentice and S. A. Jebb, “Beyond body mass index,” Obesity Reviews, vol. 2, no. 3, pp. 141–147, 2001.

[47] L. B. Houtkooper, T. G. Lohman, S. B. Going, and W. H. Howell, “Why bioelectrical impedance analysis should be used for estimating adiposity,” The American Journal of Clinical Nutrition, vol. 64, no. 3, supplement, pp. 436S–448S, 1996.

[48] B. L. Heitmann, “Impedance: a valid method in assessment of body composition?” European Journal of Clinical Nutrition, vol. 48, no. 4, pp. 228–240, 1994.

[49] R. F. Kushner, “Bioelectrical impedance analysis: a review of principles and applications,” Journal of the American College of Nutrition, vol. 11, no. 2, pp. 199–209, 1992.

[50] K. J. Ellis, “Human body composition: in vivo methods,” Physiological Reviews, vol. 80, no. 2, pp. 649–680, 2000.

[51] J. P. Després, “Intra-abdominal obesity: an untreated risk factor for type 2 diabetes and cardiovascular disease,” Journal of Endocrinological Investigation, vol. 29, no. 3, supplement, pp. 77–82, 2006.